← Insider buys

IONS

Ionis Pharmaceuticals, Inc. · Healthcare

Insiders bought $1.1M of Ionis Pharmaceuticals, Inc. in the last 12 months

1 insider bought on 1 day.

$1.1MBought, 12 mo
$78.9MSold, 12 mo
$7.1BMarket cap

IONS over the last year

Insider buy filed (1 day)

Largest buyers, last 12 months

IONS after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

311 insider filings since 2016, newest first

IONSSell

Shannon L. Devers · EVP, Chief Human Resources Ofc

$59K−7.1%Oct 19
IONSBuy

Michael R Hayden · Director

$1.1M+500.0%Jul 31
IONSSell

C Frank Bennett · EVP and Chief Scientific Officer

$1.7M−100.0%Jul 9
IONSSell

Allene M. Diaz · Director

$864K−72.6%Jul 9
IONSSell

Holly B. Kordasiewicz · EVP and Chief Development Officer

$31K−1.6%Jul 9
IONSSell

Joseph Klein III · Director

$910K−51.1%Jul 6
IONSSell

Joseph Baroldi · EVP and Chief Business Officer

$452K−54.7%Jun 30
IONSSell

Patrick R. O'Neil · EVP CLO & General Counsel

$246K−4.8%Jun 30
IONSSell

Eugene Schneider · EVP, Chf Clinical Develop Ofcr

$2.1M−25.2%Jun 30
IONSSell

Brett P Monia · Chief Executive Officer

$6.8M−25.9%Jun 26
IONSSell

Eric Swayze · EVP Research

$839K−32.8%Jun 26
IONSSell

Holly B. Kordasiewicz · EVP and Chief Development Officer

$4.5M−73.0%Jun 16
IONSSell

Spencer R Berthelsen · Director

$588K−4.9%Jun 16
IONSSell

Spencer R Berthelsen · Director

$605K−4.9%Jun 3
IONSSell

Brett P Monia · CEO

$356K−2.0%May 15
IONSSell

Joseph Loscalzo · Director

$5.8M−68.0%May 6
IONSSell

Joseph Klein III · Director

$743K−48.0%May 5
IONSSell

Joseph Baroldi · EVP and Chief Business Officer

$117K−3.0%Apr 30
IONSSell

B Lynne Parshall · Director

$381K−9.0%Apr 17
IONSSell

Kyle Jenne · EVP, Chf GL Pdt Str Ofcr

$368K−17.0%Apr 17
IONSSell

Brian Birchler · EVP, Corp, Development Ops

$73K−1.0%Apr 17
IONSSell

Joseph Baroldi · EVP and Chief Business Officer

$419K−10.0%Apr 17
IONSSell

Joseph Klein III · Director

$1.7M−67.0%Apr 2
IONSSell

Shannon L. Devers · EVP, Chief HR Ofc

$459K−27.0%Apr 2
IONSSell

Eugene Schneider · EVP, Chf Clinical Develop Ofcr

$412K−8.0%Mar 23
IONSSell

Patrick R. O'Neil · EVP CLO, GC

$764K−14.0%Mar 11
IONSSell

Joseph Loscalzo · Director

$83K−3.0%Mar 5
IONSSell

Joseph Klein III · Director

$1.7M−66.0%Mar 5
IONSSell

Joseph Baroldi · EVP and Chief Business Officer

$531K−13.0%Mar 5
IONSSell

Allene M. Diaz · Director

$4.4M−94.0%Mar 5
IONSSell

Shannon L. Devers · EVP, Chief HR Ofc

$1.6M−47.0%Mar 5
IONSSell

C Frank Bennett · EVP and Chief Scientific Officer

$6.7M−51.0%Mar 5
IONSSell

B Lynne Parshall · Director

$414K−8.0%Feb 13
IONSSell

Eric Swayze · EVP Research

$1.3M−33.0%Feb 13
IONSSell

Brett P Monia · CEO

$2.5M−10.0%Feb 10
IONSSell

Brian Birchler · EVP, Corp, Development Ops

$513K−9.0%Feb 2
IONSSell

Joseph Baroldi · EVP and Chief Business Officer

$439K−10.0%Feb 2
IONSSell

Eric Swayze · EVP Research

$512K−11.0%Feb 2
IONSSell

Eugene Schneider · EVP, Chf Clinical Develop Ofcr

$516K−8.0%Feb 2
IONSSell

Patrick R. O'Neil · EVP CLO, GC

$516K−8.0%Feb 2
IONSSell

Brett P Monia · CEO

$5.2M−18.0%Feb 2
IONSSell

Elizabeth L Hougen · EVP, Finance, CFO

$582K−5.0%Feb 2
IONSSell

C Frank Bennett · EVP and Chief Scientific Officer

$488K−6.0%Feb 2
IONSSell

Shannon L. Devers · EVP, Chief HR Ofc

$323K−15.0%Jan 23
IONSSell

Kyle Jenne · EVP, Chf GL Pdt Str Ofcr

$138K−10.0%Jan 20
IONSSell

Brian Birchler · EVP, Corp, Development Ops

$637K−12.0%Jan 20
IONSSell

Joseph Baroldi · EVP and Chief Business Officer

$610K−15.0%Jan 20
IONSSell

Eric Swayze · EVP Research

$748K−19.0%Jan 20
IONSSell

Eugene Schneider · EVP, Chf Clinical Develop Ofcr

$703K−13.0%Jan 20
IONSSell

Patrick R. O'Neil · EVP CLO, GC

$697K−12.0%Jan 20
About Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.